Antacids Market Report 2026

The antacids market size has grown steadily in recent years. It will grow from $9.94 billion in 2025 to $10.18 billion in 2026 at a compound annual growth rate (CAGR) of 2.5%. The growth in the historic period can be attributed to rising prevalence of acid reflux and heartburn, increasing awareness of digestive health, growth of retail pharmacy networks, introduction of proton pump inhibitors, expansion of liquid and chewable formulations.

The antacids market size is expected to see steady growth in the next few years. It will grow to $11.57 billion in 2030 at a compound annual growth rate (CAGR) of 3.3%. The growth in the forecast period can be attributed to increasing adoption of personalized medicine, rising demand for natural and herbal antacids, growth in e-pharmacy and online sales, technological advancements in drug delivery, expansion in emerging markets. Major trends in the forecast period include increasing over-the-counter availability, rise in combination antacid formulations, growing focus on pediatric and geriatric care, expansion of home healthcare solutions, shift towards natural and herbal antacids.

The increasing prevalence of inflammatory bowel disease (IBD) is expected to drive the growth of the antacids market. IBD refers to chronic inflammation of the digestive tract, causing discomfort and digestive disturbances. Antacids help manage symptoms like heartburn and indigestion by regulating stomach acid levels. For instance, according to the International Foundation for Gastrointestinal Disorders (IFFGD), 5-10% of the global population was estimated to have IBS in 2023, with 25-45 million affected in the United States. Furthermore, a survey by the American Gastroenterological Association across 33 countries reported that over 40% of 73,076 adult respondents experienced functional gastrointestinal disorders (FGID), which significantly impact quality of life and healthcare utilization. Therefore, the rising prevalence of IBD and related gastrointestinal conditions is fueling demand for antacids.

Key companies in the antacids market are focusing on product innovation and flavor diversification to enhance market appeal. For example, in March 2023, Wonderbelly, a US-based digestive medicine company, launched three new antacid flavors - Fruity Cereal (exclusive to Target), Strawberry Milkshake, and Watermelon Mint. While containing the same active ingredient, calcium carbonate, these products are non-GMO, vegan, and free from talc, dyes, gluten, dairy, common allergens, synthetic sweeteners, artificial flavors, parabens, and preservatives. Developed with gastroenterologists, these flavors aim to improve patient experience and adherence.

Additionally, companies are launching targeted formulations, such as anti-reflux antacids, to meet growing consumer demand for effective GERD and acid reflux relief. In June 2024, Akums Drugs and Pharmaceuticals, an India-based pharmaceutical manufacturer, introduced a chewable anti-reflux tablet combining sodium alginate and potassium bicarbonate. Approved by India’s Drugs Controller General, the dual-action formulation neutralizes stomach acid and forms a protective gel barrier, providing rapid and lasting relief from acid reflux symptoms.

Major companies operating in the antacids market are Walmart Equate LLC, Private Label, Pfizer Inc, Bayer AG, Sanofi S.A., Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim GmbH, Reckitt Benckiser Group plc, WellSpring Pharmaceutical Corporation, Xiuzheng Pharmaceutical Group Company Limited, Bausch Health Companies Inc., Sun Pharmaceuticals Industries Ltd., Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals plc, Alkem Laboratories Ltd., Conba Group Co. Ltd., Chattem Chemicals Inc., China Resources Sanjiu Medical & Pharmaceutical Co. Ltd., Thornton and Ross Ltd., McNeil Consumer Pharmaceuticals Co., Advance Pharmaceutical Inc.

North America was the largest region in the antacids market in 2025. The Middle East is expected to be the fastest-growing region in the global antacids market share. The regions covered in the antacids market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the antacids market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the antacids market by increasing the cost of imported raw materials, active pharmaceutical ingredients (APIs), and packaging components, leading to higher production costs for manufacturers. Regions such as Asia-Pacific and Europe, which serve as major production and export hubs, are particularly affected. Drug classes like proton pump inhibitors and H2 antagonists, as well as liquid and tablet formulations, face the most significant impact. However, tariffs have also encouraged local production, supply chain diversification, and cost optimization strategies, potentially boosting domestic manufacturing capabilities.

The antacids market research report is one of a series of new reports that provides antacids market statistics, including antacids industry global market size, regional shares, competitors with a antacids market share, detailed antacids market segments, market trends and opportunities, and any further data you may need to thrive in the antacids industry. This antacids market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Antacid drugs are medications used to neutralize stomach acid and treat conditions such as acid reflux, heartburn, and indigestion. They work by counteracting stomach acid to relieve discomfort and are available over-the-counter in liquid or chewable tablet forms. Antacids include drug classes such as proton pump inhibitors, H2 antagonists, acid neutralizers, and pro-motility agents, available as tablets, liquids, or powders.

The main types of antacids are proton pump inhibitors, H2 antagonists, acid neutralizers, and pro-motility agents. Proton pump inhibitors significantly reduce stomach acid production by irreversibly blocking the H+/K+ ATPase proton pump in the stomach. Formulations include tablets, liquids, powders, and others, and they are distributed through hospital pharmacies, retail pharmacies, and additional channels.

The antacids market consists of sales of Alka Seltzer, Maalox, Mylanta, Rolaids, Tums, and Pepto-Bismol. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.